Bone battle: which osteoporosis drug wins?

NCT ID NCT05010590

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compares two FDA-approved medications, romosozumab and denosumab, for treating postmenopausal osteoporosis. Researchers will measure changes in hip bone density over 12 months in 50 women at high fracture risk. The goal is to see which drug works better to strengthen bones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Romosozumab and Denosumab
What this could lead to: If successful, this study could show which medication is better at increasing bone density and reducing fracture risk in postmenopausal women.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to all women. Both drugs have known side effects like joint pain or rare bone issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTMENOPAUSAL OSTEOPOROSIS

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.